Ichnos Glenmark Innovation’s Post

We’re excited to share that we have expanded the clinical study of ISB 2001, our first-in-class trispecific antibody for the potential treatment of multiple myeloma, and dosed the first participant in India. This clinical site initiation leverages the regulatory expertise in India of our alliance partner, Glenmark Pharmaceuticals. This milestone follows the launch of our clinical study in Australia, IND clearance from the U.S. FDA, and orphan drug designation last year. Clinical study details available at https://bit.ly/4cSYitD (NCT05862012). #ClinicalTrials #ClinicalResearch #Cancer #Hematology

  • Clinical study of trispecific antibody for multiple myeloma expands to India
Kotesh Boddupalli

Senior Clinical Research Associate Global Clinical research Operations #Oncology#Immunology#Biologics_Drug Discovery

3mo

Ichnos Glenmark Innovation Congratulations Team.

Fabrizio Comper

R&D expert, AAV Gene Therapy and Protein Engineering drug development - Head of pipeline expansion at AAVantgarde Bio

3mo

congrats to the team!

See more comments

To view or add a comment, sign in

Explore topics